Tango Therapeutics, Inc. TNGX NASDAQ

Tango Therapeutics, Inc. (TNGX) has a negative trailing P/E of -23.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 59.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.22%, forward earnings yield 1.68%.

Criteria proven by this page:

• VALUE (10/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -23.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -4.22%); analyst consensus target implies downside from the current price ($15.60, 38.4%).
• Forward P/E 59.6 — analysts expect a return to profitability with estimated EPS of $0.43 for FY2030.
• Trailing Earnings Yield -4.22% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.68% as earnings recover.
• Analyst consensus target $15.60 (-38.4% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 46/100 with 3/7 criteria passed.